Steve sjuggerud latest melt up videoIt’s a very long video and after taking a break a could not start it again. Did anyone see it to the end and got the free recommendation?
I been following Steve for many years, and I have some of his service, and I think he is the real deal
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
ARQT
Does anyone know what is in his Final Surge Portfolio? This is with MattMcCall and Steve Sjuggerud?
I did and agree about Steve . I bought into him before I discovered gumshoe . I bought into some China recommendations that he says is like our ARKK which I owned one but sold. Rookie me bought at peak and was losing my very limited funds. However I happened to buy 15 (5 accidentally) and after a month its up 10%. I’m getting better happened to catch it at dip which was lower than his recommended buy price. If I had stayed with ARKK I would be down another 5%. I like Cathy Wood and may buy back in . ARQT
pharmaceutical . 2 yr potential VIDT block chain Really had to research a platform to buy from checkout cryptocurrencypriceprediction.com A note for all readers: I love this site . Thank you all who have gave me great advice, I have added 25 stocks to my watch list, and have more optimism about making better decisions now.
Yes, I watched all of it(if it’s the same one you are referring to). Made notes too but list is very long.
Nutshell: Buy buy buy like it’s 2011 (the last time he said buy buy buy). I like Steve too but got Ponzi’ed on his expensive newsletters. Like Wade Cook in 2000, with $3,000 courses and a handy dandy $2,500 news beeper.
That being said; Steve has a lot of useful knowledge but you can get the same knowledge from books, trade mags, and right here on Gumshoe. Nonetheless, the market can always turn on a dime (remember 911 and covid-19) so I learned to hedge every position no matter what. Good insurance isn’t cheap and cheap insurance isn’t good!
A few from Steve’s list: ASHS, BLACKSTONE, WASHINGTON REIT, ARBERDEEN ASIA FUND, NASDAQ BIOTECH FUND, GOLD AND TIMBER.
I have more but am suffering from writer’s cramp. Make sure to thoroughly check fundamentals and technicals (maybe even moon phases) before going for it.
The one recommendation that he actually made during the presentation was Acadia Pharmaceuticals (ACAD) which he described as a company with a $7 billion market valuation. He talked about its main drug Nuplazid. Even though I accessed the presentation today, May 5th (I actually read the transcript which you can get by attempting to exit the video at which time you will be given the option to simply read, or scan in my case, the transcript), he left ACAD as his showpiece even though ACAD suffered a major price calamity almost two months ago. Not sure why he would not take ACAD out and put another stock in.
Unfortunately for him, ACAD had a major FDA setback with its Nuplazid drug on March 8th or so, confirmed on April 5th or so. The result was a typical implosion of the stock price of a biotech that suffers any such setback. The stock price dropped from the high $40s to the mid $20s overnight and today closed at $19.40. The $7 billion market value he talked about is currently $3.1 billion. Not a harbinger of future success for his stock recommendations!
However, ACAD may actually be a good buy at this price point due to the remaining uses for which Nuplazid is still authorized and because of other drugs in the ACAD pipeline.
The other names in the presentation, some of which are set forth in the comment above, are actually winners (cherry-picked perhaps?) from another service he has run beginning in 2001, not current recommendations.
Here is the discussion of the other names in the pitch:
“In fact, when we started True Wealth back in 2001, we felt that stocks were a bad deal… So we started looking at alternative investments… from real estate and bonds to virtual banks to commodities like gold and timber.
And our readers saw double and triple-digit gains:
123% on Petro China
165% on Texas Pacific Land Trust
46% on Newmont Mining
64% on Rayonier
96% on iShares Nasdaq Biotech fund
26% on the Central Europe and Russia Fund
41% on the Aberdeen Asia Pacific Fund
192% on the Blackstone Group
54% on Washington REIT
51% on the Fairholme Fund
83% on iShares U.S. Home Construction fund
66% on China A-Shares
49% on Cresud”